GlassScriptPhysician profile
Bobby Aaron Thompson
NPI 1720020662
$4,464.27
in general payments reported to CMS, 2019-2025
31 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $548 · 2021: $926 · 2022: $885 · 2023: $831 · 2024: $520 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.83 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $715.26 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $399.49 | 2019-2024 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.57 | 2019-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $349.50 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $324.21 | 2019-2022 | |
| Pfizer INC. | $314.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $279.26 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $222.29 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $221.60 | 2022-2025 | |
| Abbott Laboratories | $174.07 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $164.38 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.25 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.75 | 2019-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $69.12 | 2022-2023 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $65.41 | 2020-2023 | Watchman Access System |
| Biohaven Pharmaceuticals, INC. | $52.13 | 2021 | |
| Sumitomo Pharma America, INC. | $50.77 | 2024-2025 | Gemtesa |
| Genentech USA, INC. | $42.73 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $41.46 | 2020 | |
| Sunovion Pharmaceuticals INC. | $37.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.47 | 2022 | |
| Seqirus USA INC | $29.84 | 2025 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $27.42 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.82 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $19.82 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $19.05 | 2024 | Veozah |
| Almatica Pharma LLC | $14.97 | 2022 | |
| Medtronic, INC. | $14.33 | 2024 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $11.26 | 2021 | |
| Merck Sharp & Dohme LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.